NEW YORK, Feb. 15 (GenomeWeb News) - Qiagen said today that its wholly owned subsidiary GenoVision has licensed technology for haplotype-specific extraction of DNA from Lawrenceville, NJ-based Generation Biotech.
Under the terms of the agreement, GenoVision receives exclusive rights for the worldwide commercialization of the haplotype-specific extraction in all applications. Further financial terms were not disclosed.
The haplotype-specific extraction method physically separates DNA into its maternal and paternal alleles, enabling researchers or clinicians to determine the exact location of a mutation on both copies of the genome, Qiagen said.
Qiagen also said that the technology has been validated for use with a suite of its magnetic bead-based and automated DNA-purification technology.